ivacaftor - Profile

What are the generic drug sources for ivacaftor and what is the scope of patent protection?

Ivacaftor is the generic ingredient in three branded drugs marketed by Vertex Pharms Inc and Vertex Pharms, and is included in five NDAs. There are fifty-five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ivacaftor has two hundred and fifty-seven patent family members in thirty-six countries.

There are two tentative approvals for this compound.

Summary for ivacaftor

International Patents:	257
US Patents:	55
Tradenames:	3
Applicants:	2
NDAs:	5
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ivacaftor

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ivacaftor

Constraining patent/regulatory exclusivity:

8,883,206*PED

Dosage:

GRANULE;ORAL

Constraining patent/regulatory exclusivity:

10,646,481*PED

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for IVACAFTOR

Applicant	Application No.	Strength	Dosage Form
		150MG	TABLET; ORAL
		75MG	GRANULE;ORAL
		50MG	GRANULE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for IVACAFTOR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KALYDECO	Oral Granules	ivacaftor	25 mg, 50 mg and 75 mg	207925	1	2022-04-13
KALYDECO	Tablets	ivacaftor	150 mg	203188	1	2020-06-10

US Patents and Regulatory Information for ivacaftor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-004	May 3, 2023		RX	Yes	No	11,752,106*PED				Y
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-004	May 3, 2023		RX	Yes	No	12,214,083*PED				Y
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-004	May 3, 2023		RX	Yes	No	11,147,770*PED				Y

Expired US Patents for ivacaftor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-004	May 3, 2023	8,629,162
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-002	Mar 17, 2015	8,629,162
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-003	Apr 29, 2019	8,629,162

EU/EMA Drug Approvals for ivacaftor

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Vertex Pharmaceuticals (Ireland) Limited	Kalydeco	ivacaftor	EMEA/H/C/002494Kalydeco tablets are indicated:As monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4.4 and 5.1).In a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the CFTR gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G, and 3849+10kbC→T.In a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (CF) who have at least one F508del mutation in the CFTR gene (see section 5.1).Kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4.4 and 5.1).	Authorised	no	no	no	2012-07-23

International Patents for ivacaftor

Country	Patent Number	Title	Estimated Expiration
Mexico	365890
Hong Kong	1152707
Cyprus	1116116

Supplementary Protection Certificates for ivacaftor

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1773816	35/2015	Austria		PRODUCT NAME: N-(5-HYDROXY-2,4DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLIN-3-CARBOXAMID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/782/001, EU/1/12/782/002 (MITTEILUNG) 20120725
1773816	1590036-8	Sweden		PRODUCT NAME: N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3- CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/12/782/001, 2012-07-25; DEN 2025-05-21 MEDDELADE PRV BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD: 1590036-8,1690018-5, 1490016-1
3170818	2020/035	Ireland		PRODUCT NAME: A COMBINATION OF (A) 3-(6-(1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5- YL)CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID (LUMACAFTOR) AND (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3- CARBOXAMIDE (IVACAFTOR) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1059 20151124

Investment Scenario, Market Dynamics, and Financial Trajectory for Ivacaftor

Last updated: February 3, 2026

Summary

Ivacaftor (marketed as Kalydeco) is a first-in-class CFTR potentiator developed by Vertex Pharmaceuticals for the treatment of cystic fibrosis (CF). Since its approval in 2012, the drug has reshaped the CF treatment landscape, providing targeted therapy for specific genetic mutations. This analysis examines the investment prospects, market dynamics, and financial trajectory of ivacaftor, incorporating current market data, competitive landscape, regulatory environment, and growth opportunities.

---

1. Overview of Ivacaftor and Its Therapeutic Indication

Parameter	Details
Therapeutic Class	CFTR potentiator
Brand Name	Kalydeco
Mechanism of Action	Enhances gating function of CFTR protein at specific mutations
Approved Indications	Specific mutations (e.g., G551D), with expanded indications in combination therapies
Market Launch	2012
Primary Market	United States, Europe, emerging markets

Figure 1: Approved Indications and Usage for Ivacaftor

Mutation Types	Description
Gating mutations	G551D, S1251N, G178R, G1349D, among others
Residual function mutations	Patients with certain mutations allowing partial CFTR activity

---

2. Market Dynamics

2.1 Market Penetration and Revenue Trends

Year	Global Sales (USD millions)	Growth Rate	Notes
2012	$100	--	Launch year
2015	$480	38% CAGR	Market expansion and new indications
2018	$1,100	20% CAGR	Increased approvals, expanded label
2021	$1,700	14% CAGR	Approvals for additional mutations, biosimilars awareness
2022	$1,840	8.2%	Maturation of dominant markets

Note: A conservative CAGR after 2018 reflects market saturation and the evolving treatment paradigm with subsequent drugs

2.2 Competitive Landscape & Pipeline

Competitors	Key Products	Mechanisms	Regulatory Status
Vertex	Ivacaftor; Lumacaftor/Ivacaftor (Orkambi); Tezacaftor/Ivacaftor (Symdeko); Elexacaftor/Tezacaftor/Ivacaftor (Trikafta)	CFTR correctors and potentiators	Established; expanding indications; combination therapies driving growth
Healthcare Innovators	Galicaftor, AbbVie’s ABBV-3067, and AI models	Novel molecules and delivery methods	Early-stage R&D; potential disruptors in mutation coverage

Implication: The competitive landscape is dominated by Vertex, with several next-generation drugs extending market share, especially via combination therapies like Trikafta.

2.3 Regulatory & Policy Environment

Key Policies	Impact
Orphan drug designation	Extended market exclusivity (up to 7 years in US, 10 in EU)
Price regulation trends	Pressure on pricing, especially in Europe, may impact profitability
Healthcare reimbursements	Expanding access via insurance coverage, though national policies vary

---

3. Financial Trajectory and Investment Outlook

3.1 Sales Forecast 2023-2028

Year	Projected Global Sales (USD millions)	Assumptions
2023	$2,000	Market penetrance plateau; new mutations coverage increases slightly
2024	$2,200	Launch of expanded indications; increased biosimilar awareness
2025	$2,400	Regulatory approvals for pediatric populations, if achieved
2026	$2,600	Maximal market penetration with new combination therapies
2027	$2,700	Competition intensifies; mature market phase
2028	$2,800	Slight growth driven by pipeline and pipeline approvals

Note: The CAGR over five years approximates 7.5%, reflecting mature market trends and inherent growth limitations.

3.2 Cost and Revenue Structures

Element	Details
Manufacturing Cost	Estimated at 10-15% of net sales
Pricing Strategy	List prices range from $300,000 to $350,000 annually per patient in developed countries
Market Access	Reimbursed via public and private payers, with tiered pricing in emerging markets
Profit Margins	Estimated gross margins above 70% due to high R&D and manufacturing efficiency

3.3 Investment Considerations

Strengths	Risks
Established market position	Competition from newer drugs and biosimilars
Extensive pipeline combining with ivacaftor	Pricing pressures and regulatory hurdles
Significant unmet needs coverage in CF mutations	Patent expiration around 2030, potential generics

---

4. Strategic Opportunities & Challenges

4.1 Opportunities

• Pipeline Expansion: The development of next-generation modulators (e.g., ABP-654) and combination therapies could extend effective treatment to broader mutation spectra.

• Expansion into Emerging Markets: Growing healthcare infrastructure in Asia, Latin America, and Africa offers significant revenue expansion potential.

• Pediatric Use & Early Intervention: Regulatory approvals for pediatric populations could drive long-term adherence and cumulative sales growth.

4.2 Challenges

• Patent Expirations: Potential entry of biosimilars post-2030 may erode market share and profit margins.

• Pricing & Reimbursement Policies: Heightened scrutiny over drug pricing could constrain sales growth in some regions.

• Pipeline Risks: R&D failures or delays in next-generation drugs could impair future revenue streams.

---

5. Comparative Analysis with Similar Marketed Drugs

Drug	Market Year	Peak Sales (USD millions)	Market Life	Key Indications	Competitive Edge
Ivacaftor (Kalydeco)	2012–Present	$1,840 (2022)	Ongoing	Gating mutations of CFTR	First-in-class, mutation-specific
Lumacaftor/Ivacaftor (Orkambi)	2015–Present	~$1,400 (2019)	Ongoing	Homozygous F508del CF mutation	Combines corrector & potentiator
Tezacaftor/Ivacaftor (Symdeko)	2018–Present	~$950 (2021)	Ongoing	F508del mutation	Improved safety profile
Elexacaftor/Tezacaftor/Ivacaftor (Trikafta)	2019–Present	$3,100 (2022)	Growing rapidly	Broad mutation coverage, significant sales boost	Market leader in CF therapy

Note: Ivacaftor’s success has primarily been driven by mutation-specific efficacy, highlighting the importance of genetic targeting in CF.

---

6. Future Trends & Market Outlook

Trend	Impact
Expansion of approved indications in pediatrics	Extended market lifespan and increased sales volume
Integration of gene-editing technologies	Potential long-term disruption of current therapies
Competitive biosimilar entry	Price competition; small impact in high-cost niche markets
Policy-driven pricing reforms	Potential margin compression in sensitive markets

---

7. Conclusion and Investment Takeaways

• Mature but Growing Market: Ivacaftor sustains a high-value niche, with steady growth driven by expanding indications and combination therapies.

• Pipeline & Next-Generation Drugs: Continued R&D investments by Vertex and competitors suggest medium-term pipeline risks and opportunities.

• Revenue & Profitability Stability: High gross margins and strong market position support dividend and R&D reinvestment potential, despite pricing pressures.

• Long-Term Risks: Patent expirations, biosimilar competition, and regulatory reforms pose significant challenges to sustained pricing power.

Overall, ivacaftor presents a compelling investment case rooted in its pioneering status and ongoing expansion, balanced against competitive and regulatory headwinds.

---

Key Takeaways

• Ivacaftor remains the cornerstone of mutation-specific cystic fibrosis treatment with projected annual sales approaching $2.8 billion by 2028.
• The drug’s growth is increasingly driven by combination therapies (e.g., Trikafta), surpassing initial monotherapy sales.
• Market expansion into emerging markets and pediatric populations offers significant upside potential.
• Regulatory and patent landscapes will influence competition, profitability, and lifecycle management.
• Stakeholders should monitor pipeline advancements and policy shifts impacting drug pricing and reimbursement.

---

FAQs

1. What is the current market size and future growth forecast for ivacaftor?

The global sales of ivacaftor were approximately $1.84 billion in 2022, with a projected compound annual growth rate (CAGR) of around 7.5% through 2028, reaching approximately $2.8 billion.

2. How does ivacaftor compare to its competitors in CF therapy?

Ivacaftor is the first approved CFTR potentiator, leading in mutation-specific efficacy. Its successor, the triple combination Trikafta (elexacaftor/tezacaftor/ivacaftor), has eclipsed monotherapy sales, offering broader mutation coverage and higher efficacy.

3. What are the key patent and regulatory risks for ivacaftor?

Patent protection extends into the early 2030s, after which biosimilars could enter the market. Regulatory policies focused on drug pricing could also impact revenue and margins.

4. What growth opportunities exist beyond existing indications?

Potential expansion into pediatric populations, additional mutations, and emerging markets could boost sales. R&D on next-generation modulators aims to address non-responders or resistant mutations.

5. How will pricing pressures influence the profitability of ivacaftor?

Pricing in Europe and emerging markets faces increasing government scrutiny. Vertex’s ability to maintain premium pricing hinges on clinical superiority and market exclusivity until patent expiry.

---

References

[1] Vertex Pharmaceuticals Annual Reports, 2012-2022.
[2] EvaluatePharma, "Cystic Fibrosis Market Overview," 2022.
[3] U.S. Food and Drug Administration (FDA) Approvals Database, 2012–2022.
[4] European Medicines Agency (EMA), Drug Approvals, 2012–2022.
[5] Market Research Future, "CF Market Forecast 2023-2028," 2023.